Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)
 
 • Company Description   
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Number of Employees: 317

 
 • Price / Volume Information   
Yesterday's Closing Price: $26.14 Daily Weekly Monthly
20 Day Moving Average: 1,117,355 shares
Shares Outstanding: 103.78 (millions)
Market Capitalization: $2,712.85 (millions)
Beta: 1.80
52 Week High: $28.23
52 Week Low: $8.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.00% 1.46%
12 Week 53.40% 50.14%
Year To Date 37.80% 22.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1600 SIERRA POINT PKWY
-
BRISBANE,CA 94005
USA		 ph: 415-660-5320
fax: -		 kfortner@nurixtx.com http://www.nurixtx.com
 
 • General Corporate Information   
Officers
Arthur T. Sands - President and Chief Executive Officer
Julia P. Gregory - Chairman
Hans van Houte - Chief Financial Officer
Roy D. Baynes - Director
Roger Dansey - Director

Peer Information
Nurix Therapeutics, Inc. (CORR.)
Nurix Therapeutics, Inc. (RSPI)
Nurix Therapeutics, Inc. (CGXP)
Nurix Therapeutics, Inc. (BGEN)
Nurix Therapeutics, Inc. (GTBP)
Nurix Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67080M103
SIC: 2834
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 05/01/26
Next Expected EPS Date: 10/08/26
Share - Related Items
Shares Outstanding: 103.78
Most Recent Split Date: (:1)
Beta: 1.80
Market Capitalization: $2,712.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/08/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.71
Price/Cash Flow: -
Price / Sales: 73.79
EPS Growth
vs. Year Ago Period: -55.77%
vs. Previous Quarter: -2.53%
Sales Growth
vs. Year Ago Period: -79.47%
vs. Previous Quarter: 44.64%
ROE
08/31/26 - -
05/31/26 - -76.09
02/28/26 - -64.21
ROA
08/31/26 - -
05/31/26 - -57.31
02/28/26 - -48.44
Current Ratio
08/31/26 - -
05/31/26 - 6.34
02/28/26 - 6.01
Quick Ratio
08/31/26 - -
05/31/26 - 6.34
02/28/26 - 6.01
Operating Margin
08/31/26 - -
05/31/26 - -928.44
02/28/26 - -411.37
Net Margin
08/31/26 - -
05/31/26 - -928.44
02/28/26 - -411.37
Pre-Tax Margin
08/31/26 - -
05/31/26 - -929.18
02/28/26 - -410.32
Book Value
08/31/26 - -
05/31/26 - 3.89
02/28/26 - 4.65
Inventory Turnover
08/31/26 - -
05/31/26 - -
02/28/26 - -
Debt-to-Equity
08/31/26 - -
05/31/26 - 0.00
02/28/26 - 0.00
Debt-to-Capital
08/31/26 - -
05/31/26 - 0.00
02/28/26 - 0.00
 

Powered by Zacks Investment Research ©